Tags

Type your tag names separated by a space and hit enter

Stereotactic breast biopsy is accurate, minimally invasive, and cost effective.
Am J Surg. 1996 May; 171(5):474-6.AJ

Abstract

BACKGROUND

We reviewed our experience with stereotactic core needle breast biopsy (SCNBB) for accuracy, complication rate, and staging profile of malignancies diagnosed.

METHODS

Since March 1993, 530 stereotactic biopsies were performed. Of these, 25 cases underwent stereotactic core needle biopsy with subsequent wire-guided biopsy.

RESULTS

In 25 patients with stereotactic and open biopsy, there was an accuracy for SCNBB of 96%. The number of biopsies rose from 100 to 250 biopsies annually, with an equivalent pre-test positive predictive value for mammography (17% to 19% historical versus 20% with SCNBB). The total number of de novo cancer diagnoses have increased from a mean of 57 to a mean of 71 annually. The percentage of tumors in situ, stage I or stage II, has increased from 60% to 69%.

CONCLUSIONS

Stereotactic core needle biopsy combines a high accuracy with a low complication rate. Its aggressive application for tissue diagnosis in suspicious nonpalpable mammographic lesions has increased the proportion of early (in situ and T1 or T2) tumors discovered, and increased the total number of breast cancers diagnosed.

Authors+Show Affiliations

Department of Surgery, Madigan Army Medical Center, Fort Lewis Washington 98431, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8651388

Citation

Pettine, S, et al. "Stereotactic Breast Biopsy Is Accurate, Minimally Invasive, and Cost Effective." American Journal of Surgery, vol. 171, no. 5, 1996, pp. 474-6.
Pettine S, Place R, Babu S, et al. Stereotactic breast biopsy is accurate, minimally invasive, and cost effective. Am J Surg. 1996;171(5):474-6.
Pettine, S., Place, R., Babu, S., Williard, W., Kim, D., & Carter, P. (1996). Stereotactic breast biopsy is accurate, minimally invasive, and cost effective. American Journal of Surgery, 171(5), 474-6.
Pettine S, et al. Stereotactic Breast Biopsy Is Accurate, Minimally Invasive, and Cost Effective. Am J Surg. 1996;171(5):474-6. PubMed PMID: 8651388.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stereotactic breast biopsy is accurate, minimally invasive, and cost effective. AU - Pettine,S, AU - Place,R, AU - Babu,S, AU - Williard,W, AU - Kim,D, AU - Carter,P, PY - 1996/5/1/pubmed PY - 1996/5/1/medline PY - 1996/5/1/entrez SP - 474 EP - 6 JF - American journal of surgery JO - Am J Surg VL - 171 IS - 5 N2 - BACKGROUND: We reviewed our experience with stereotactic core needle breast biopsy (SCNBB) for accuracy, complication rate, and staging profile of malignancies diagnosed. METHODS: Since March 1993, 530 stereotactic biopsies were performed. Of these, 25 cases underwent stereotactic core needle biopsy with subsequent wire-guided biopsy. RESULTS: In 25 patients with stereotactic and open biopsy, there was an accuracy for SCNBB of 96%. The number of biopsies rose from 100 to 250 biopsies annually, with an equivalent pre-test positive predictive value for mammography (17% to 19% historical versus 20% with SCNBB). The total number of de novo cancer diagnoses have increased from a mean of 57 to a mean of 71 annually. The percentage of tumors in situ, stage I or stage II, has increased from 60% to 69%. CONCLUSIONS: Stereotactic core needle biopsy combines a high accuracy with a low complication rate. Its aggressive application for tissue diagnosis in suspicious nonpalpable mammographic lesions has increased the proportion of early (in situ and T1 or T2) tumors discovered, and increased the total number of breast cancers diagnosed. SN - 0002-9610 UR - https://www.unboundmedicine.com/medline/citation/8651388/Stereotactic_breast_biopsy_is_accurate_minimally_invasive_and_cost_effective_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9610(96)00007-4 DB - PRIME DP - Unbound Medicine ER -